1,418 research outputs found
Effects of Low-Energy Laser Irradiation on Sperm Cells Dynamics of Rabbit (Oryctolagus Cuniculus)
Infertility is a world disease in which a couple is unable to achieve pregnancy. There are numerous parameters to determinate fertility; nevertheless, sperm motility is by consensus one of the most important attributes to evaluate male fertility. Contributions to a better understanding of this crucial parameter are imperative; hence, the aim of this investigation was to assess the effect of low-energy laser irradiation on sperm cell dynamics in thawed samples that were cryopreserved. We used a 405 nm blue laser beam to irradiate spermatic cells from rabbit inside a temperature-controlled dispersion chamber at 37 °C; then, we applied an image recognizing system to calculate individual sperm trajectories and velocities. We found that sperms raise its motility after irradiation suggesting that λ=405 nm is an optimal wavelength for spermatic photo-stimulation
Sperm Hyperactivation and Capacitation Induced By Light Stimuli in Cryopreserved Semen
In mammals, such as rabbits, there are some factors involved in possible fertilization, from complex changes in the membrane of the sperm to obstruction or non-existent of vas deferens, which creates problems in the number and quality of sperm. In this work, we report the effects of rabbit sperm motility and capacitation of cryopreserved semen samples under light stimuli. The sperm velocities were correlated with the percentage of capacitated and non-capacitated sperm seen with a fluorescent dye. Consequently, we analyzed the specific correlations between irradiation times, supplied energy, and fertility parameters.
KEYWORDS THAT SEARCHED RELATED TO THE ARTICLE ON THE WEB
sperm meaning, capacitation, human sperm, capacitation occurs in, what is sperm, capacitation of sperm, sperm lifetime, fertilization definition, fertilization meaning, capacitation meaning, mechanism of fertilization,sperm capacitation, capacitate meaning, fertilization takes place in, capacitate, capacitation of sperm occurs in, capacitation of sperms, capacitated, definition of fertilizatio
Simulation of the CMS Resistive Plate Chambers
The Resistive Plate Chamber (RPC) muon subsystem contributes significantly to
the formation of the trigger decision and reconstruction of the muon trajectory
parameters. Simulation of the RPC response is a crucial part of the entire CMS
Monte Carlo software and directly influences the final physical results. An
algorithm based on the parametrization of RPC efficiency, noise, cluster size
and timing for every strip has been developed. Experimental data obtained from
cosmic and proton-proton collisions at TeV have been used for
determination of the parameters. A dedicated validation procedure has been
developed. A good agreement between the simulated and experimental data has
been achieved.Comment: to be published in JINS
The medicine selection process in four large university hospitals in Brazil: Does the DTC have a role?
The highly prevalent BRCA2 mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple origins
BRCA2-c.2808_2811del (3036delACAA) is one of the most reported
germ line mutations in non-Ashkenazi breast cancer patients. We
investigated its genetic origin in 51 Spanish carrier families that
were genotyped with 11 13q polymorphic markers. Three independent
associated haplotypes were clearly distinguished accounting for
23 [west Castilla y León (WCL)], 20 [east Castilla y León (ECL)]
and 6 (South of Spain) families. Mutation age was estimated with
the Disequilibrium Mapping using Likelihood Estimation software
in a range of 45–68 and 45–71 generations for WCL and ECL haplotypes,
respectively. The most prevalent variants, c.2808_2811del
and c.2803G > A, were located in a double-hairpin loop structure
(c.2794–c.2825) predicted by Quikfold that was proposed as a mutational
hotspot. To check this hypothesis, random mutagenesis was
performed over a 923 bp fragment of BRCA2, and 86 DNA variants
were characterized. Interestingly, three mutations reported in the
mutation databases (c.2680G > A, c.2944del and c.2957dup) were
replicated and 20 affected the same position with different nucleotide
changes. Moreover, five variants were placed in the same hairpin loop
of c.2808_2811del, and one affected the same position (c.2808A > G).
In conclusion, our results support that at least three different mutational
events occurred to generate c.2808_2811del. Other highly
prevalent DNA variants, such as BRCA1-c.68_69delAG, BRCA2-
c.5946delT and c.8537delAG, are concentrated in hairpin loops, suggesting
that these structures may represent mutational hotspots
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
Background: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. Methods: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. Results: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93–1.04, P=0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89–1.06, P=0.5) mutation carriers. Conclusion: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out. A Osorio1, R L Milne2, G Pita3, P Peterlongo4,5, T Heikkinen6, J Simard7, G Chenevix-Trench8, A B Spurdle8, J Beesley8, X Chen8, S Healey8, KConFab9, S L Neuhausen10, Y C Ding10, F J Couch11,12, X Wang11, N Lindor13, S Manoukian4, M Barile14, A Viel15, L Tizzoni5,16, C I Szabo17, L Foretova18, M Zikan19, K Claes20, M H Greene21, P Mai21, G Rennert22, F Lejbkowicz22, O Barnett-Griness22, I L Andrulis23,24, H Ozcelik24, N Weerasooriya23, OCGN23, A-M Gerdes25, M Thomassen25, D G Cruger26, M A Caligo27, E Friedman28,29, B Kaufman28,29, Y Laitman28, S Cohen28, T Kontorovich28, R Gershoni-Baruch30, E Dagan31,32, H Jernström33, M S Askmalm34, B Arver35, B Malmer36, SWE-BRCA37, S M Domchek38, K L Nathanson38, J Brunet39, T Ramón y Cajal40, D Yannoukakos41, U Hamann42, HEBON37, F B L Hogervorst43, S Verhoef43, EB Gómez García44,45, J T Wijnen46,47, A van den Ouweland48, EMBRACE37, D F Easton49, S Peock49, M Cook49, C T Oliver49, D Frost49, C Luccarini50, D G Evans51, F Lalloo51, R Eeles52, G Pichert53, J Cook54, S Hodgson55, P J Morrison56, F Douglas57, A K Godwin58, GEMO59,60,61, O M Sinilnikova59,60, L Barjhoux59,60, D Stoppa-Lyonnet61, V Moncoutier61, S Giraud59, C Cassini62,63, L Olivier-Faivre62,63, F Révillion64, J-P Peyrat64, D Muller65, J-P Fricker65, H T Lynch66, E M John67, S Buys68, M Daly69, J L Hopper70, M B Terry71, A Miron72, Y Yassin72, D Goldgar73, Breast Cancer Family Registry37, C F Singer74, D Gschwantler-Kaulich74, G Pfeiler74, A-C Spiess74, Thomas v O Hansen75, O T Johannsson76, T Kirchhoff77, K Offit77, K Kosarin77, M Piedmonte78, G C Rodriguez79, K Wakeley80, J F Boggess81, J Basil82, P E Schwartz83, S V Blank84, A E Toland85, M Montagna86, C Casella87, E N Imyanitov88, A Allavena89, R K Schmutzler90, B Versmold90, C Engel91, A Meindl92, N Ditsch93, N Arnold94, D Niederacher95, H Deißler96, B Fiebig97, R Varon-Mateeva98, D Schaefer99, U G Froster100, T Caldes101, M de la Hoya101, L McGuffog49, A C Antoniou49, H Nevanlinna6, P Radice4,5 and J Benítez1,3 on behalf of CIMB
Analisis de las respuestas moleculares profundas alcanzadas por las multiples secuencias de tratamientos con ITKS en LMC. Estudio de largo seguimiento del registro español de LMC
Poster [PC-231]
Introducción: Cinco inhibidores de tirosina cinasa (ITKs) están disponibles para el tratamiento de pacientes con leucemia mieloide crónica en fase crónica (LMC-FC). Analizamos las diferentes secuencias de ITKs utilizadas como terapia para la LMC-FC en un análisis a largo plazo en vida real.
Métodos: En un análisis retrospectivo de cohortes, se incluyeron pacientes con LMC-FC tratados en la práctica clínica con diferentes ITKs en el Registro Español de LMC (RELMC) (17 hospitales de todo el país) entre 2000 y 2014. El objetivo principal del estudio fue describir la secuencia del tratamiento con ITKs en la práctica de la vida real y la última respuesta molecular profunda (DMR) (MR4, MR4.5 o transcrito indetectable) para cada esquema.
Resultados: Nuestro análisis incluyó 862 pacientes con LMC en 1º FC tratados con ITKs en 1ª línea o después de interferón alfa. Datos demográficos demográficos: 517 H, 345 M, mediana de edad: 52 años (14-94a). Distribución del Índice Sokal (bajo 49% Inter 38% Alto 13%), Índice EURO (bajo 50% Inter 45% Alto 5%), Índice EUTOS (bajo 93% Alto 7%), Índice LT-EUTOS (bajo 68 % Inter 25% Alto 7%). Esquemas de tratamiento: la Tabla 1 resume todos los esquemas utilizados y la última respuesta molecular. Los pacientes se dividieron en 4 grupos según el tratamiento con ITKs. Grupo 1: solo tratados con Imatinib 394 p (45, 7%) Grupo 2: Imatinib y luego 2ºGITKs debido a intolerancia o fallo 170 p (19, 7%) (12 esquemas de tratamiento secuenciales diferentes con ITKs) Grupo 3: 2ºGITKs en 1ª línea 91 p (13 esquemas secuenciales) (10, 5%) Grupo 4: Interferón alfa y luego ITKs 207 p (24%) (9 esquemas secuenciales). La Figura 1 resume la evolución de diferentes tratamientos alrededor de los 14 años. Última respuesta molecular profunda: con una mediana de seguimiento de 82 meses (1-351 m) desde el diagnóstico, 77 m (1-311 m) desde el primer tratamiento y 70 m (1-191 m) desde el primer tratamiento con ITK. Las tasas de respuesta molecular profunda para cada grupo fueron (G1: DMR 65% MMR 13% No MMR 15%, G2: DMR 46% MMR 24% No MMR 17%, G3: DMR 62% MMR 13% No MMR 12%, G4: DMR 53% MMR 17% No MMR 18%). Supervivencia a largo plazo (SLP o SG): no se encontraron diferencias estadísticas entre los grupos de tratamiento, ya sea desde el diagnóstico, el primer tratamiento o el primer ITK. Alcanzar una respuesta profunda garantiza mejores resultados. Variables predictivas de respuesta: los índices SOKAL, EUTOS, EURO y LT-EUTOS continúan siendo útiles para predecir el resultado a largo plazo.
Conclusiones: En el contexto de un registro multicéntrico basado en hospitales, el tratamiento con ITKs es muy variable, con un gran número de secuencias diferentes de ITKs. Con una mediana de seguimiento de 7 años la tasa de respuesta molecular profunda es aproximadamente del 60% en pacientes tratados con imatinib y que no necesitan cambio de ITKs, y en aquellos tratados en 1º línea con 2ºGITKs(a pesar de su corto seguimiento), pero parece menor en pacientes tratados con imatinib que necesitan cambiar a 2ºGITKs. Los resultados de supervivencia fueron similares para todos los grupos
Observation of the decay
The decay is observed in collision
data corresponding to an integrated luminosity of 3 fb recorded by the
LHCb detector at centre-of-mass energies of 7 TeV and 8 TeV. This is the first
observation of this decay channel, with a statistical significance of 15
standard deviations. The mass of the meson is measured to be
MeV/c. The branching fraction ratio
is measured to be 0.0115\,\pm\, 0.0012\, ^{+0.0005}_{-0.0009}.
In both cases, the first uncertainty is statistical and the second is
systematic. No evidence for non-resonant or decays is found.Comment: All figures and tables, along with any supplementary material and
additional information, are available at
https://lhcbproject.web.cern.ch/lhcbproject/Publications/LHCbProjectPublic/LHCb-PAPER-2015-033.htm
Observation of resonances consistent with pentaquark states in decays
Observations of exotic structures in the channel, that we refer to
as pentaquark-charmonium states, in decays are
presented. The data sample corresponds to an integrated luminosity of 3/fb
acquired with the LHCb detector from 7 and 8 TeV pp collisions. An amplitude
analysis is performed on the three-body final-state that reproduces the
two-body mass and angular distributions. To obtain a satisfactory fit of the
structures seen in the mass spectrum, it is necessary to include two
Breit-Wigner amplitudes that each describe a resonant state. The significance
of each of these resonances is more than 9 standard deviations. One has a mass
of MeV and a width of MeV, while the second
is narrower, with a mass of MeV and a width of MeV. The preferred assignments are of opposite parity, with one
state having spin 3/2 and the other 5/2.Comment: 48 pages, 18 figures including the supplementary material, v2 after
referee's comments, now 19 figure
- …